Introduction: The impact of therapeutic hypothermia (TH) on outcomes of percutaneous coronary intervention (PCI) and the optimal antiplatelet treatment remains debatable.

Methods: Electronic databases were searched for randomized trials and observational studies to evaluate the available clinical evidence comparing the use of clopidogrel versus newer P2Y12 antagonists in cases of TH after PCI. The primary outcome was in-hospital definite stent thrombosis while the secondary outcomes were in-hospital mortality and major bleeding. Fixed-effects risk ratios (RRs) were estimated using Mantel–Haenszel method.

Results: The final analysis included five studies with a total of 290 patients. There was no difference in the incidence of stent thrombosis (RR 0.92; 95% CI 0.35–2.38), in-hospital mortality (RR 1.38; 95% CI 0.72–2.65), and major bleeding (RR 0.89; 95% CI 0.33–2.40) between patients receiving clopidogrel versus those receiving newer agents.

Conclusions: This meta-analysis showed no difference between clopidogrel and newer antiplatelet agents in the incidence of stent thrombosis or in-hospital mortality for PCI in cases of TH. Further randomized studies are needed to explore the optimal dual antiplatelet treatment in TH.

Document Type


Publication Date


Notes/Citation Information

Published in Cardiology and Therapy, v. 7, issue 2, p. 185-189.

© The Author(s) 2018

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Digital Object Identifier (DOI)


Related Content

To view enhanced digital features for this article go to https://doi.org/10.6084/m9.figshare.7007816.

The online version of this article (https://doi.org/10.1007/s40119-018-0118-x) contains supplementary material, which is available to authorized users.

40119_2018_118_MOESM1_ESM.pdf (213 kB)
Supplementary material 1

40119_2018_118_MOESM2_ESM.pdf (14 kB)
Supplementary material 2

40119_2018_118_MOESM3_ESM.pdf (257 kB)
Supplementary material 3

Included in

Cardiology Commons